Tanvex BioPharma Inc
TWSE:6541
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Republic Services Inc
NYSE:RSG
|
US |
Tanvex BioPharma Inc
Revenue
Tanvex BioPharma Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tanvex BioPharma Inc
TWSE:6541
|
Revenue
NT$401m
|
CAGR 3-Years
162%
|
CAGR 5-Years
322%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
SSE:688235
|
Revenue
¥38.2B
|
CAGR 3-Years
59%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Polaris Group
TWSE:6550
|
Revenue
NT$40.6m
|
CAGR 3-Years
85%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Tanvex BioPharma Inc
Glance View
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.
See Also
What is Tanvex BioPharma Inc's Revenue?
Revenue
401m
TWD
Based on the financial report for Dec 31, 2025, Tanvex BioPharma Inc's Revenue amounts to 401m TWD.
What is Tanvex BioPharma Inc's Revenue growth rate?
Revenue CAGR 5Y
322%
Over the last year, the Revenue growth was 1 056%. The average annual Revenue growth rates for Tanvex BioPharma Inc have been 162% over the past three years , 322% over the past five years .
